Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 25, 2017Journal of Clinical OncologyOpen Access

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

RCRobert ChenXuzhou Medical College
Pier Luigi Zinzani
Pier Luigi ZinzaniUniversité Claude Bernard Lyon 1MFMichelle A. FanalePfizer (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chen et al. (2017) studied this question.

synapsesocial.com/papers/6a7ca24072ca93b7bdc89243https://doi.org/10.1200/jco.2016.72.1316
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Revised Response Criteria for Malignant Lymphoma2007 · 4,467 citations
  2. 2Standard therapy of advanced Hodgkin lymphoma2009 · 86 citations
  3. 3PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome2016 · 819 citations